Medicare card competition heats up

This year’s top dermatology posts on Managed Healthcare Executive include stories about Gen Z sunscreen trends and increasing incidences of ringworm and jock itch.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in early January 2025 and will be priced at parity to the IV version of Opdivo.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain medicine that might offer hope for those struggling with acute pain issues who want to avoid opioids and NSAIDs.

Cardiomyopathies currently have no cures, but many of these disorders are prime candidates for gene therapies.